MXPA05012465A - Heterociclos de nitrogeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma. - Google Patents
Heterociclos de nitrogeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma.Info
- Publication number
- MXPA05012465A MXPA05012465A MXPA05012465A MXPA05012465A MXPA05012465A MX PA05012465 A MXPA05012465 A MX PA05012465A MX PA05012465 A MXPA05012465 A MX PA05012465A MX PA05012465 A MXPA05012465 A MX PA05012465A MX PA05012465 A MXPA05012465 A MX PA05012465A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- peroxisome proliferator
- activated receptors
- conditions
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Los compuestos de la formula (I) proporcionan agentes farmacologicos que se unen a receptores activados por el proliferador de peroxisoma (PPARs). De acuerdo con lo anterior, los compuestos de la presente invencion son utiles para el tratamiento de condiciones mediadas por la actividad del receptor de PPAR en mamiferos. Tales condiciones incluyen dislipidemia, hiperlipidemia, hipercolesteremia, aterosclerosis, hipertrigliceridemia, falla cardiaca, infarto al miocardio, enfermedades vasculares, enfermedades cardiovasculares, hipertension, obesidad, inflamacion, artritis, cancer, enfermedad de Alzheimer, trastornos de la piel, enfermedades respiratorias, trastornos oftalmicos, enfermedades inflamatorias del intestino, colitis ulcerativa, enfermedad de Crohn, y condiciones en donde estan implicadas la tolerancia danada a glucosa, hiperglicemia y resistencia a insulina, tal como diabetes de tipo 1 y de tipo 2, y sindrome X.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47206703P | 2003-05-20 | 2003-05-20 | |
| PCT/EP2004/005434 WO2004103995A1 (en) | 2003-05-20 | 2004-05-19 | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05012465A true MXPA05012465A (es) | 2006-01-30 |
Family
ID=33476920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05012465A MXPA05012465A (es) | 2003-05-20 | 2004-05-19 | Heterociclos de nitrogeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7652061B2 (es) |
| EP (1) | EP1638963B1 (es) |
| JP (1) | JP4637843B2 (es) |
| KR (2) | KR100849747B1 (es) |
| CN (1) | CN1795193B (es) |
| AR (1) | AR044399A1 (es) |
| AT (1) | ATE442365T1 (es) |
| AU (1) | AU2004240754B9 (es) |
| BR (1) | BRPI0410779A (es) |
| CA (1) | CA2525764C (es) |
| CL (1) | CL2004001169A1 (es) |
| CO (1) | CO5650248A2 (es) |
| DE (1) | DE602004023080D1 (es) |
| EC (1) | ECSP056175A (es) |
| ES (1) | ES2331131T3 (es) |
| IS (1) | IS8160A (es) |
| MA (1) | MA27777A1 (es) |
| MX (1) | MXPA05012465A (es) |
| NO (1) | NO20056056L (es) |
| PE (1) | PE20050157A1 (es) |
| PT (1) | PT1638963E (es) |
| RU (1) | RU2374241C2 (es) |
| TN (1) | TNSN05295A1 (es) |
| TW (1) | TW200524918A (es) |
| WO (1) | WO2004103995A1 (es) |
| ZA (1) | ZA200508905B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0412557A (pt) * | 2003-07-28 | 2006-09-19 | Reddys Lab Inc Dr | forma de dosagem farmacêutica de eventos cardiovasculares |
| AU2005258248A1 (en) * | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| EA200700117A1 (ru) | 2004-06-24 | 2007-06-29 | Инсайт Корпорейшн | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов |
| PE20060594A1 (es) * | 2004-09-09 | 2006-08-18 | Novartis Ag | Composicion farmaceutica que contiene un agonista de ppar |
| ES2380556T3 (es) * | 2005-06-27 | 2012-05-16 | Newtree Co., Ltd. | Métodos para prevenir y tratar estados mediados por PPAR usando macelignano. |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
| PT2402319T (pt) | 2006-03-31 | 2017-12-11 | Novartis Ag | Inibidores de dgat |
| AR063311A1 (es) | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| EA201100189A1 (ru) | 2008-07-15 | 2011-08-30 | Новартис Аг | Гетероарильные производные в качестве ингибиторов dgat1 |
| JP5062097B2 (ja) * | 2008-08-21 | 2012-10-31 | 富士通株式会社 | 情報処理装置、情報処理装置の制御方法、および情報処理装置の制御プログラム |
| US8491927B2 (en) | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| US8829194B2 (en) | 2010-10-07 | 2014-09-09 | Novartis Ag | Crystalline forms of the sodium salt of (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid |
| EA024059B1 (ru) | 2011-01-13 | 2016-08-31 | Новартис Аг | Гетероциклические производные и их применение в лечении неврологических расстройств |
| EP2663308A1 (en) | 2011-01-13 | 2013-11-20 | Novartis AG | Bace-2 inhibitors for the treatment of metabolic disorders |
| US8614195B2 (en) | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| EP2697240B1 (en) | 2011-04-14 | 2015-09-16 | Novartis AG | Glycoside derivatives and uses thereof |
| KR20140048235A (ko) | 2011-07-08 | 2014-04-23 | 노파르티스 아게 | 신규 트리플루오로메틸-옥사디아졸 유도체 및 질환의 치료에서의 그의 용도 |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| WO2013043744A2 (en) | 2011-09-21 | 2013-03-28 | Inception 1, Inc. | Tricyclic compounds useful as neurogenic and neuroprotective agents |
| EP2766358B1 (en) | 2011-10-13 | 2016-06-22 | Novartis AG | Novel oxazine derivatives and their use in the treatment of disease |
| AU2012345557A1 (en) | 2011-11-28 | 2014-06-26 | Novartis Ag | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP2841432A1 (en) | 2012-04-27 | 2015-03-04 | Novartis AG | Tetrahydropyran dgat1 inhibitors |
| CA2870336A1 (en) | 2012-04-27 | 2013-10-31 | Novartis Ag | Cyclic bridgehead ether dgat1 inhibitors |
| EA201690713A1 (ru) | 2013-10-04 | 2016-08-31 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| DK3119397T3 (da) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| WO2015198199A1 (en) | 2014-06-23 | 2015-12-30 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof. |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| AU2016322552B2 (en) | 2015-09-14 | 2021-03-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| JP6946304B2 (ja) | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3437651A1 (en) | 2017-08-03 | 2019-02-06 | Université de Strasbourg | Peptides for treatment and prevention of nonalcoholic fatty liver disease |
| BR112020011913A2 (pt) | 2017-12-14 | 2020-11-24 | Universite De Strasbourg | peptídeos e composição farmacêutica |
| WO2020110008A1 (en) | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| CN113166204A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽 |
| EP4233890A3 (en) | 2018-12-21 | 2023-10-11 | Université de Strasbourg | Peptides for treatment and prevention of diabetes and associated disorders |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
| WO2023152698A1 (en) | 2022-02-10 | 2023-08-17 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5045540A (en) * | 1990-05-25 | 1991-09-03 | Warner-Lambert Co. | Amino acid derivatives with angiotensin II antagonist properties |
| ATE224366T1 (de) * | 1997-10-31 | 2002-10-15 | Hoffmann La Roche | D-prolinderivate |
| WO2000059874A1 (en) | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE |
| GB0024362D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| TW200303742A (en) * | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
-
2004
- 2004-05-19 AR ARP040101732A patent/AR044399A1/es not_active Application Discontinuation
- 2004-05-19 CN CN2004800140213A patent/CN1795193B/zh not_active Expired - Fee Related
- 2004-05-19 KR KR1020057022001A patent/KR100849747B1/ko not_active IP Right Cessation
- 2004-05-19 MX MXPA05012465A patent/MXPA05012465A/es active IP Right Grant
- 2004-05-19 ES ES04739269T patent/ES2331131T3/es not_active Expired - Lifetime
- 2004-05-19 US US10/556,988 patent/US7652061B2/en not_active Expired - Fee Related
- 2004-05-19 CA CA2525764A patent/CA2525764C/en not_active Expired - Fee Related
- 2004-05-19 RU RU2005139525/04A patent/RU2374241C2/ru not_active IP Right Cessation
- 2004-05-19 KR KR1020087000342A patent/KR100909918B1/ko not_active IP Right Cessation
- 2004-05-19 PE PE2004000511A patent/PE20050157A1/es not_active Application Discontinuation
- 2004-05-19 EP EP04739269A patent/EP1638963B1/en not_active Expired - Lifetime
- 2004-05-19 BR BRPI0410779-9A patent/BRPI0410779A/pt not_active IP Right Cessation
- 2004-05-19 JP JP2006529884A patent/JP4637843B2/ja not_active Expired - Fee Related
- 2004-05-19 TW TW093114121A patent/TW200524918A/zh unknown
- 2004-05-19 DE DE602004023080T patent/DE602004023080D1/de not_active Expired - Lifetime
- 2004-05-19 AT AT04739269T patent/ATE442365T1/de active
- 2004-05-19 PT PT04739269T patent/PT1638963E/pt unknown
- 2004-05-19 WO PCT/EP2004/005434 patent/WO2004103995A1/en active Application Filing
- 2004-05-19 AU AU2004240754A patent/AU2004240754B9/en not_active Ceased
- 2004-05-20 CL CL200401169A patent/CL2004001169A1/es unknown
-
2005
- 2005-11-03 ZA ZA200508905A patent/ZA200508905B/xx unknown
- 2005-11-15 MA MA28605A patent/MA27777A1/fr unknown
- 2005-11-18 TN TNP2005000295A patent/TNSN05295A1/en unknown
- 2005-11-18 EC EC2005006175A patent/ECSP056175A/es unknown
- 2005-11-30 IS IS8160A patent/IS8160A/is unknown
- 2005-12-15 CO CO05126527A patent/CO5650248A2/es not_active Application Discontinuation
- 2005-12-20 NO NO20056056A patent/NO20056056L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05012465A (es) | Heterociclos de nitrogeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma. | |
| MY134965A (en) | Heterocyclic compounds and methods of use | |
| BRPI0412380A (pt) | compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos | |
| MXPA06003055A (es) | Compuestos organicos. | |
| Cobb et al. | N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists. 3. Structure− activity relationship and optimization of the N-aryl substituent | |
| DE602006008576D1 (de) | Antidiabetische bicyclische verbindungen | |
| MX2009006795A (es) | Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma. | |
| TW200621220A (en) | Combination of organic compounds | |
| CL2007002347A1 (es) | Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm | |
| BRPI0407180A (pt) | Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto | |
| RU2010120808A (ru) | Производное амина, обладающее активностью антагониста npy y5 рецептора, и его применение | |
| Xue et al. | Design, Synthesis, and Structure–Activity and Structure–Pharmacokinetic Relationship Studies of Novel [6, 6, 5] Tricyclic Fused Oxazolidinones Leading to the Discovery of a Potent, Selective, and Orally Bioavailable FXa Inhibitor | |
| UA85405C2 (ru) | Производные 1,1'-(1,2-этиндиил)бис-бензола как ингибиторы ртр-1в | |
| AR047669A1 (es) | Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion | |
| MX2011009244A (es) | Derivado de piridina. | |
| CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
| MX2009003222A (es) | Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad. | |
| WO2005115383A3 (en) | Substituted triazoles as modulators of ppar and methods of their preparation | |
| ATE372782T1 (de) | Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin- abhängigen diabetes | |
| DE60023492D1 (de) | Glucagon antagonisten/inverse agonisten | |
| CY1111576T1 (el) | Υποκατεστημενα παραγωγα μεθυλενο αμιδης ως ρυθμιστες των φωσφατασων πρωτεϊνης τυροσινης(ptps) | |
| EP1948161A4 (en) | METHOD OF PREVENTION AND TREATMENT WITH MACELIGNAN OF MEDIA MEDIA BY PPAR | |
| JP2015502918A5 (es) | ||
| EA023861B1 (ru) | Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений | |
| MX2009010790A (es) | Derivados de heteroarilo biciclico fusionados. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |